An Open-label Study to Evaluate Safety, Tolerability, and Efficacy of CB03-154 in Subjects Diagnosed With Epilepsy

Recruiting now · Phase 2

Conditions studied: Focal Epilepsy

In brief

CB03-154 is an investigational drug developed by Shanghai Zhimeng Biopharma Inc. for the treatment of Focal Epilepsy.

Key facts

Study ID
NCT07238868
Run by
Shanghai Zhimeng Biopharma, Inc.
People needed
144
Starts
2025-08-14
Expected to finish
2029-06-01
Last updated by the study team
2025-11-20

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.